ClinicalTrials.gg
CompletedNCT00904748A1481272Updated Feb 1, 2021Results posted

A Relative Bioavailability Study Between Two Formulations Of Sildenafil Citrate

A Phase 1 interventional study of sildenafil citrate 100 mg CT and sildenafil citrate 100 mg CT in Erectile Dysfunction, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 1 site in Brazil. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-01.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing sildenafil in Erectile Dysfunction — 1 open to participants now, 1 under way, 1 of them phase 3. sildenafil · Erectile Dysfunction.

Enrollment
37th of 50
47 · median 108
Started
2010
with 2 others
Phase 1
6 of 50
none open now
Registered
31st of 50
by date
Lead sponsor
23 of 50
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 50 studies testing sildenafil in Erectile Dysfunction, this one is the 37th largest by enrollment, is one of 3 that started in 2010, is one of 6 in phase 1, and was the 31st registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

1 of the 50 studies testing sildenafil in Erectile Dysfunction is open now. Recruiting first, the newest first:

About sildenafil

sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 50 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing sildenafil in Erectile Dysfunction, or all of them as a file.
02

Study summary

The purpose of this study is to perform a relative bioavailability study between two formulations of sildenafil citrate.

Read the detailed description

Bio-equivalence between two formulations of sildenafil citrate

03

Conditions studied

  • Erectile Dysfunction

Browse trials for

Keywords

  • Sildenafil
  • Bio-equivalence
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • higher or equal to 18,5 and lower or equal than 29,9 kg/m2.
  • Good health conditions or without significant disease, at medical discretion, according to the rules defined in the Protocol, and evaluations undergone: clinical history, pulse and blood pressure measurements, physical and psychological examination, and complementary laboratory examination.
  • Able to understand the study nature and objective, including the risks and adverse effects and willing to cooperate with the investigator and act according to all the trial requirements, which is confirmed by signing the Form.

Exclusion criteria

Exclusion Criteria:

  • to the study drug or to the chemically related compounds; history of serious adverse reactions or hypersensitivity to any drug.
  • History or presence of hepatic or gastrointestinal diseases, or other condition that affects the drug absorption, distribution, excretion or metabolism
  • History of hepatic, renal, lung, gastrointestinal, epileptic, hematological or psychiatric disease; hypo or hypertension of whatever etiology which demands treatment with drugs; history or occurrence of myocardial infarction, angina and/or cardiac failure;
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Test 1

    Drug: sildenafil citrate 100 mg CT

  • Experimental
    Test 2

    Drug: sildenafil citrate 100 mg CT

  • Active comparator
    Reference

    Drug: Viagra®

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC 0-t)

    Area under the blood concentration-time profile from time zero to last experimentally determined concentration measured in nanograms\*hour/milliliter (ng\*hr/mL).

    Time frame: Day 1 (Period 1), Day 8 (Period 2), and Day 15 (Period 3): Pre-dose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose

  2. Maximum Plasma Concentration (Cmax)

    Maximum plasma concentration measured in nanograms per milliliter (ng/mL).

    Time frame: Day 1 (Period 1), Day 8 (Period 2), and Day 15 (Period 3): Pre-dose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose

Secondary outcomes

  1. Area Under the Curve From 0 to Infinity (AUC 0-inf )

    Area under the blood concentration-time profile from time zero extrapolated to infinite time measured in nanograms \*hour/milliliter (ng\*hr/mL).

    Time frame: Day 1 (Period 1), Day 8 (Period 2), and Day 15 (Period 3): Pre-dose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose

  2. Time to Maximum Plasma Concentration (Tmax)

    Time at which maximum plasma concentration (Cmax) occurred.

    Time frame: Day 1 (Period 1), Day 8 (Period 2), and Day 15 (Period 3): Pre-dose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose

  3. Half-life (T 1/2)

    Terminal elimination half-life.

    Time frame: Day 1 (Period 1), Day 8 (Period 2), and Day 15 (Period 3): Pre-dose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose

  4. Number of Participants With Clinically Significant Findings in Vital Signs

    Clinically significant abnormalities in blood pressure (BP), pulse, and temperature reported as an adverse event. Clinically significant = values outside the normal range and/or values judged as significant by the investigator (normal range: systolic BP 100-140 mmHg; diastolic BP 60- 90 mmHg; temperature 35-37°Celsius). Pulse rate based on investigator discretion.

    Time frame: Day 1 (Period 1), Day 8 (Period 2), and Day 15 (Period 3): Pre-dose and 0.5, 1, 2, 4, 8 and 12 hours post-dose.

07

Results

Posted Apr 4, 2011

Participant flow

Participant flow — Overall Study
MilestoneSequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6
Started888888
Received treatment888878
Completed777678
Not completed111210
Withdrew: Withdrawal by subject111200
Withdrew: Adverse event000010

Outcome measures

PrimaryArea Under the Curve (AUC 0-t)

Area under the blood concentration-time profile from time zero to last experimentally determined concentration measured in nanograms\*hour/milliliter (ng\*hr/mL).

Time frame:
Day 1 (Period 1), Day 8 (Period 2), and Day 15 (Period 3): Pre-dose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose
Reported as:
Mean · ng*hr/mL
Area Under the Curve (AUC 0-t)
ng*hr/mLTest 1: 100 mg Chewable, Without WaterTest 2: 100 mg Chewable, With WaterReference: 100 mg Coated, With Water
Area Under the Curve (AUC 0-t)1467.00 ± 560.991458.45 ± 602.731493.53 ± 615.59
Statistical analysis
  • Test 1: 100 mg Chewable, Without Water vs Reference: 100 mg Coated, With Water · ANOVA · Ratio between geometric means: 98.68 · 90% CI 92.03 to 105.82Estimated value = ratio (% reference).
  • Test 2: 100 mg Chewable, With Water vs Reference: 100 mg Coated, With Water · ANOVA · Ratio between geometric means: 97.23 · 90% CI 90.67 to 104.26Estimated value = ratio (% reference).
PrimaryMaximum Plasma Concentration (Cmax)

Maximum plasma concentration measured in nanograms per milliliter (ng/mL).

Time frame:
Day 1 (Period 1), Day 8 (Period 2), and Day 15 (Period 3): Pre-dose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax)
ng/mLTest 1: 100 mg Chewable, Without WaterTest 2: 100 mg Chewable, With WaterReference: 100 mg Coated, With Water
Maximum Plasma Concentration (Cmax)439.38 ± 198.25434.38 ± 211.53532.31 ± 217.32
Statistical analysis
  • Test 1: 100 mg Chewable, Without Water vs Reference: 100 mg Coated, With Water · ANOVA · Ratio between geometric means: 80.83 · 90% CI 72.38 to 90.26Estimated value = ratio (% reference).
  • Test 2: 100 mg Chewable, With Water vs Reference: 100 mg Coated, With Water · ANOVA · Ratio between geometric means: 78.76 · 90% CI 70.53 to 87.96Estimated value = ratio (% reference).
SecondaryArea Under the Curve From 0 to Infinity (AUC 0-inf )

Area under the blood concentration-time profile from time zero extrapolated to infinite time measured in nanograms \*hour/milliliter (ng\*hr/mL).

Time frame:
Day 1 (Period 1), Day 8 (Period 2), and Day 15 (Period 3): Pre-dose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose
Reported as:
Mean · ng*hr/mL
Area Under the Curve From 0 to Infinity (AUC 0-inf )
ng*hr/mLTest 1: 100 mg Chewable, Without WaterTest 2: 100 mg Chewable, With WaterReference: 100 mg Coated, With Water
Area Under the Curve From 0 to Infinity (AUC 0-inf )1547.92 ± 588.481534.66 ± 618.861573.81 ± 648.32
Statistical analysis
  • Test 1: 100 mg Chewable, Without Water vs Reference: 100 mg Coated, With Water · ANOVA · Ratio between geometric means: 99.12 · 90% CI 92.76 to 105.93Estimated value = ratio (% reference).
  • Test 2: 100 mg Chewable, With Water vs Reference: 100 mg Coated, With Water · ANOVA · Ratio between geometric means: 97.84 · 90% CI 91.56 to 104.56Estimated value = ratio (% reference).
SecondaryTime to Maximum Plasma Concentration (Tmax)

Time at which maximum plasma concentration (Cmax) occurred.

Time frame:
Day 1 (Period 1), Day 8 (Period 2), and Day 15 (Period 3): Pre-dose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose
Reported as:
Mean · hours
Time to Maximum Plasma Concentration (Tmax)
hoursTest 1: 100 mg Chewable, Without WaterTest 2: 100 mg Chewable, With WaterReference: 100 mg Coated, With Water
Time to Maximum Plasma Concentration (Tmax)1.46 ± 0.811.29 ± 0.711.28 ± 0.85
Statistical analysis
  • Test 1: 100 mg Chewable, Without Water vs Reference: 100 mg Coated, With Water · ANOVA · Mean difference (final values): 0.18 · 90% CI -0.14 to 0.50
  • Test 2: 100 mg Chewable, With Water vs Reference: 100 mg Coated, With Water · ANOVA · Mean difference (final values): 0.01 · 90% CI -0.27 to 0.28
SecondaryHalf-life (T 1/2)

Terminal elimination half-life.

Time frame:
Day 1 (Period 1), Day 8 (Period 2), and Day 15 (Period 3): Pre-dose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose
Reported as:
Mean · hours
Half-life (T 1/2)
hoursTest 1: 100 mg Chewable, Without WaterTest 2: 100 mg Chewable, With WaterReference: 100 mg Coated, With Water
Half-life (T 1/2)2.96 ± 0.632.84 ± 0.742.93 ± 0.81
SecondaryNumber of Participants With Clinically Significant Findings in Vital Signs

Clinically significant abnormalities in blood pressure (BP), pulse, and temperature reported as an adverse event. Clinically significant = values outside the normal range and/or values judged as significant by the investigator (normal range: systolic BP 100-140 mmHg; diastolic BP 60- 90 mmHg; temperature 35-37°Celsius). Pulse rate based on investigator discretion.

Time frame:
Day 1 (Period 1), Day 8 (Period 2), and Day 15 (Period 3): Pre-dose and 0.5, 1, 2, 4, 8 and 12 hours post-dose.
Reported as:
Number · participants
Number of Participants With Clinically Significant Findings in Vital Signs
participantsTest 1: 100 mg Chewable, Without WaterTest 2: 100 mg Chewable, With WaterReference: 100 mg Coated, With Water
Number of Participants With Clinically Significant Findings in Vital Signs010

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Test 1: 100 mg Chewable, Without Water—0/47 (0%)3/47 (6.4%)
Test 2: 100 mg Chewable, With Water—0/47 (0%)3/47 (6.4%)
Reference: 100 mg Coated, With Water—0/47 (0%)3/47 (6.4%)
Formulation Unspecified—0/47 (0%)18/47 (38.3%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventTest 1: 100 mg Chewable, Without WaterTest 2: 100 mg Chewable, With WaterReference: 100 mg Coated, With WaterFormulation Unspecified
Laboratory change: urineGeneral disorders0/470/470/478/47
Laboratory change: red blood cell countGeneral disorders0/470/470/474/47
HeadacheGeneral disorders3/472/472/470/47
Laboratory change: glucoseGeneral disorders0/470/470/473/47
Laboratory change: triglyceridesGeneral disorders0/470/470/472/47
Laboratory change: cholesterolGeneral disorders0/470/470/472/47
Laboratory changes unspecifiedGeneral disorders0/470/470/472/47
NauseaGeneral disorders1/470/471/470/47
Loose stoolsGeneral disorders1/470/470/470/47
HypotensionGeneral disorders0/471/470/470/47

Baseline characteristics

Age, Continuous
Age, Continuous(years)Entire Study Population
Mean29.3 (18 to 45)
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female0
Male48
08

Study locations

1 site
  • Pfizer Investigational Site
    Braganca Paulista, SP 12916-900, Brazil
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2009
First posted
May 20, 2009
Start
Jan 2010
Primary completionActual
Mar 2010
CompletionActual
Mar 2010
Results first posted
Apr 4, 2011
Last update
Feb 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00904748
Responsible party
Sponsor
First posted
May 20, 2009
Start date
Jan 2010
Primary completion
Mar 2010
Completion
Mar 2010
Results posted
Apr 4, 2011
Last update
Feb 1, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion